secwatch.observer — SEC 8-K summary
======================================

Issuer:     Werewolf Therapeutics, Inc. (HOWL)
CIK:        0001785530
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001785530-24-000026
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Werewolf Therapeutics Q2 2024 net loss $17.2M; positive clinical data for WTX-124 and WTX-330
--------------------------------------------------------------------------------

- Net loss of $17.2M in Q2 2024 vs $5.1M in Q2 2023; R&D expenses rose to $15.3M from $9.6M.
- Cash and equivalents $135.3M at June 30, 2024; sufficient to fund operations through at least Q1 2026.
- WTX-124 monotherapy achieved 3 objective responses, including 1 complete response at 18 mg IV Q2W RDE.
- WTX-330 showed 1 unconfirmed partial response in melanoma; therapeutically relevant exposure levels achieved.
- Updated WTX-124 combination data and expansion arms expected H2 2024; WTX-330 data in Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785530/000178553024000026/0001785530-24-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785530/000178553024000026/howl-20240808.htm
  HTML page:      https://secwatch.observer/filing/0001785530-24-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer